These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

178 related items for PubMed ID: 17341621

  • 1. Expression of the E2F family of transcription factors and its clinical relevance in ovarian cancer.
    Reimer D, Sadr S, Wiedemair A, Goebel G, Concin N, Hofstetter G, Marth C, Zeimet AG.
    Ann N Y Acad Sci; 2006 Dec; 1091():270-81. PubMed ID: 17341621
    [Abstract] [Full Text] [Related]

  • 2. Clinical relevance of E2F family members in ovarian cancer--an evaluation in a training set of 77 patients.
    Reimer D, Sadr S, Wiedemair A, Stadlmann S, Concin N, Hofstetter G, Müller-Holzner E, Marth C, Zeimet AG.
    Clin Cancer Res; 2007 Jan 01; 13(1):144-51. PubMed ID: 17200349
    [Abstract] [Full Text] [Related]

  • 3. E2Fs mediate a fundamental cell-cycle deregulation in high-grade serous ovarian carcinomas.
    De Meyer T, Bijsmans IT, Van de Vijver KK, Bekaert S, Oosting J, Van Criekinge W, van Engeland M, Sieben NL.
    J Pathol; 2009 Jan 01; 217(1):14-20. PubMed ID: 18991331
    [Abstract] [Full Text] [Related]

  • 4. E2F3a is critically involved in epidermal growth factor receptor-directed proliferation in ovarian cancer.
    Reimer D, Hubalek M, Riedle S, Skvortsov S, Erdel M, Concin N, Fiegl H, Müller-Holzner E, Marth C, Illmensee K, Altevogt P, Zeimet AG.
    Cancer Res; 2010 Jun 01; 70(11):4613-23. PubMed ID: 20460525
    [Abstract] [Full Text] [Related]

  • 5. Expression of the E2F family of transcription factors during murine development.
    Kusek JC, Greene RM, Nugent P, Pisano MM.
    Int J Dev Biol; 2000 Apr 01; 44(3):267-77. PubMed ID: 10853823
    [Abstract] [Full Text] [Related]

  • 6. MiR-15 and miR-16 are direct transcriptional targets of E2F1 that limit E2F-induced proliferation by targeting cyclin E.
    Ofir M, Hacohen D, Ginsberg D.
    Mol Cancer Res; 2011 Apr 01; 9(4):440-7. PubMed ID: 21454377
    [Abstract] [Full Text] [Related]

  • 7. E2F1 in gliomas: a paradigm of oncogene addiction.
    Alonso MM, Alemany R, Fueyo J, Gomez-Manzano C.
    Cancer Lett; 2008 May 18; 263(2):157-63. PubMed ID: 18334281
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Characterization of E2F8, a novel E2F-like cell-cycle regulated repressor of E2F-activated transcription.
    Christensen J, Cloos P, Toftegaard U, Klinkenberg D, Bracken AP, Trinh E, Heeran M, Di Stefano L, Helin K.
    Nucleic Acids Res; 2005 May 18; 33(17):5458-70. PubMed ID: 16179649
    [Abstract] [Full Text] [Related]

  • 11. Heterogeneous cross-talk of E2F family members is crucially involved in growth modulatory effects of interferon-gamma and EGF.
    Reimer D, Sadr S, Wiedemair A, Concin N, Hofstetter G, Marth C, Zeimet AG.
    Cancer Biol Ther; 2006 Jul 18; 5(7):771-6. PubMed ID: 16721044
    [Abstract] [Full Text] [Related]

  • 12. From G0 to S phase: a view of the roles played by the retinoblastoma (Rb) family members in the Rb-E2F pathway.
    Sun A, Bagella L, Tutton S, Romano G, Giordano A.
    J Cell Biochem; 2007 Dec 15; 102(6):1400-4. PubMed ID: 17979151
    [Abstract] [Full Text] [Related]

  • 13. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
    Dressman HK, Berchuck A, Chan G, Zhai J, Bild A, Sayer R, Cragun J, Clarke J, Whitaker RS, Li L, Gray J, Marks J, Ginsburg GS, Potti A, West M, Nevins JR, Lancaster JM.
    J Clin Oncol; 2007 Feb 10; 25(5):517-25. PubMed ID: 17290060
    [Abstract] [Full Text] [Related]

  • 14. E2F-6 suppresses growth-associated apoptosis of human hematopoietic progenitor cells by counteracting proapoptotic activity of E2F-1.
    Kikuchi J, Shimizu R, Wada T, Ando H, Nakamura M, Ozawa K, Furukawa Y.
    Stem Cells; 2007 Oct 10; 25(10):2439-47. PubMed ID: 17600109
    [Abstract] [Full Text] [Related]

  • 15. E2F - at the crossroads of life and death.
    Polager S, Ginsberg D.
    Trends Cell Biol; 2008 Nov 10; 18(11):528-35. PubMed ID: 18805009
    [Abstract] [Full Text] [Related]

  • 16. Structure of the Rb C-terminal domain bound to E2F1-DP1: a mechanism for phosphorylation-induced E2F release.
    Rubin SM, Gall AL, Zheng N, Pavletich NP.
    Cell; 2005 Dec 16; 123(6):1093-106. PubMed ID: 16360038
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Noninvasive assessment of E2F-1-mediated transcriptional regulation in vivo.
    Monfared P, Winkeler A, Klein M, Li H, Klose A, Hoesel M, Waerzeggers Y, Korsching S, Jacobs AH.
    Cancer Res; 2008 Jul 15; 68(14):5932-40. PubMed ID: 18632648
    [Abstract] [Full Text] [Related]

  • 19. Transforming growth factor-beta inhibits telomerase through SMAD3 and E2F transcription factors.
    Lacerte A, Korah J, Roy M, Yang XJ, Lemay S, Lebrun JJ.
    Cell Signal; 2008 Jan 15; 20(1):50-9. PubMed ID: 17881189
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.